Clinical Trial Update: Prophylactic Use of Entecavir for HBsAg Positive Lymphoma Patients Treated With Rituximab-based Immunochemotherapy [Phase 4]

View source ↗

Summary

Phase 4 clinical trial investigates prophylactic entecavir to prevent hepatitis B reactivation in HBsAg-positive lymphoma patients treated with rituximab-based …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B
• Non-hodgkin Lymphoma

Drugs mentioned

• Baraclude (entecavir)

Snippet

Sponsor: Peking University | Conditions: Hepatitis B | Phase 4 | Status: UNKNOWN